Risk of Incident Venous Thromboembolism Among Patients With Bullous Pemphigoid or Pemphigus Vulgaris: A Nationwide Cohort Study With Meta‐Analysis

Background Bullous pemphigoid (BP) and pemphigus vulgaris (PV) share similar pathophysiology with venous thromboembolism (VTE) involving platelet activation, immune dysregulation, and systemic inflammation. Nevertheless, their associations have not been well established. Methods and Results To examine the risk of incident VTE among patients with BP or PV, we performed a nationwide cohort study using Taiwan's National Health Insurance Research Database and enrolled 12 162 adults with BP or PV and 12 162 controls. A Cox regression model considering stabilized inverse probability weighting was used to calculate the hazard ratios (HRs) for incident VTE associated with BP or PV. To consolidate the findings, a meta-analysis that incorporated results from the present cohort study with previous literature was also conducted. Compared with controls, patients with BP or PV had an increased risk for incident VTE (HR, 1.87 [95% CI, 1.55-2.26]; P<0.001). The incidence of VTE was 6.47 and 2.20 per 1000 person-years in the BP and PV cohorts, respectively. The risk for incident VTE significantly increased among patients with BP (HR, 1.85 [95% CI, 1.52-2.24]; P<0.001) and PV (HR, 1.99 [95% CI, 1.02-3.91]; P=0.04). In the meta-analysis of 8 studies including ours, BP and PV were associated with an increased risk for incident VTE (pooled relative risk, 2.17 [95% CI, 1.82-2.62]; P<0.001). Conclusions BP and PV are associated with an increased risk for VTE. Preventive approaches and cardiovascular evaluation should be considered particularly for patients with BP or PV with concomitant risk factors such as hospitalization or immobilization.

[1]  Zihua Chen,et al.  Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy , 2023, Frontiers in Immunology.

[2]  Ling-Ling Lee,et al.  Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis. , 2022, JAMA dermatology.

[3]  J. Silverberg,et al.  Association of autoimmune blistering disease, and specifically, pemphigus vulgaris, with cardiovascular disease and its risk factors: a systematic review and meta-analysis , 2022, Archives of Dermatological Research.

[4]  W. Shen,et al.  Risk of All-Cause Mortality, Cardiovascular Disease Mortality, and Cancer Mortality in Patients With Bullous Pemphigoid. , 2021, JAMA dermatology.

[5]  Ling-Ling Lee,et al.  Association of Psoriasis With Incident Venous Thromboembolism and Peripheral Vascular Disease: A Systematic Review and Meta-analysis. , 2021, JAMA dermatology.

[6]  Tzeng-Ji Chen,et al.  Association between alopecia areata and retinal diseases: A nationwide population-based cohort study. , 2021, Journal of the American Academy of Dermatology.

[7]  Sung-Jen Hung,et al.  Radiation-induced bullous pemphigoid in a patient with Kaposi's sarcoma , 2021, Zhōnghuá Pífūkē Yīxué Zázhì.

[8]  Chun-Ying Wu,et al.  Statins did not reduce the mortality risk in patients with bullous pemphigoid: A population-based cohort study , 2021, Dermatologica Sinica.

[9]  Chung-Pin Li,et al.  Association of Immunosuppressants with Mortality of Patients with Bullous Pemphigoid: A Nationwide Population-Based Cohort Study , 2021, Dermatology.

[10]  Y. Kanthi,et al.  Inflammation, Infection and Venous Thromboembolism. , 2021, Circulation research.

[11]  S. Massberg,et al.  Interplay between inflammation and thrombosis in cardiovascular pathology , 2021, Nature Reviews Cardiology.

[12]  K. Wei,et al.  Venous thromboembolism in a case with pemphigus vulgaris after infusion of rituximab plus systemic glucocorticoids and azathioprine: A possible adverse effect of rituximab? , 2021 .

[13]  Toshiyuki Yamamoto,et al.  Erythrodermic bullous pemphigoid , 2021, Zhōnghuá Pífūkē Yīxué Zázhì.

[14]  Chung-Pin Li,et al.  Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study. , 2020, Diabetes research and clinical practice.

[15]  M. Preusser,et al.  Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. , 2020, Blood.

[16]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[17]  M. Cushman,et al.  Venous Thromboembolism Research Priorities: A Scientific Statement From the American Heart Association and the International Society on Thrombosis and Haemostasis , 2020, Circulation.

[18]  J. Silverberg,et al.  Association of inflammatory skin diseases with venous thromboembolism in US adults , 2020, Archives of Dermatological Research.

[19]  M. Amagai,et al.  Autoimmune bullous skin diseases, pemphigus and pemphigoid. , 2020, The Journal of allergy and clinical immunology.

[20]  J. Silverberg,et al.  Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients. , 2020, Journal of the American Academy of Dermatology.

[21]  C. Lemarié,et al.  Cytokine and chemokine regulation of venous thromboembolism , 2020, Journal of thrombosis and haemostasis : JTH.

[22]  T. Tvedt,et al.  The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials , 2019, Blood.

[23]  Jessica M Franklin,et al.  Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.

[24]  K. Kridin,et al.  The Risk of Pulmonary Embolism in Patients With Pemphigus: A Population-Based Large-Scale Longitudinal Study , 2019, Front. Immunol..

[25]  K. Kridin,et al.  Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. , 2019, Autoimmunity reviews.

[26]  T. Tung,et al.  Increased risk for incident thyroid diseases in people with psoriatic disease: A cohort study , 2019, Journal of the American Academy of Dermatology.

[27]  P. Jagielski,et al.  The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: Case-control study in a specialized Polish center. , 2019, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[28]  P. Wells,et al.  Venous Thromboembolism: Advances in Diagnosis and Treatment , 2018, JAMA.

[29]  Mei-Ching Lee,et al.  Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease , 2018, JAMA.

[30]  D. Zillikens,et al.  Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid , 2017, Experimental dermatology.

[31]  Soyun Cho,et al.  Misclassification of study designs in the dermatology literature , 2017, Journal of the American Academy of Dermatology.

[32]  I. Dudkiewicz,et al.  Venous thromboembolism in patients with pemphigus: A cohort study , 2017, Journal of the American Academy of Dermatology.

[33]  A. Aslam,et al.  Bullous pemphigoid and pemphigus vulgaris , 2017, British Medical Journal.

[34]  Carlo José Freire Oliveira,et al.  Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris , 2017, Mediators of inflammation.

[35]  C. Hammers,et al.  Mechanisms of Disease: Pemphigus and Bullous Pemphigoid. , 2016, Annual review of pathology.

[36]  Soo Young Kim,et al.  A newly developed tool for classifying study designs in systematic reviews of interventions and exposures showed substantial reliability and validity. , 2016, Journal of clinical epidemiology.

[37]  J. Hansen,et al.  COPD and risk of venous thromboembolism and mortality in a general population , 2015, European Respiratory Journal.

[38]  J. Ioannidis,et al.  Nationwide Population Science: Lessons From the Taiwan National Health Insurance Research Database. , 2015, JAMA internal medicine.

[39]  F. Rosendaal,et al.  Increased risk of venous thromboembolism in patients with bullous pemphigoid , 2015, Thrombosis and Haemostasis.

[40]  J. Reserva,et al.  Pemphigus vegetans with coexistent herpes simplex infection and deep venous thrombosis of the lower extremities , 2015, BMJ Case Reports.

[41]  E. Berti,et al.  Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk , 2015, PloS one.

[42]  M. Cugno,et al.  Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[43]  K. Ng,et al.  Risks of venous thromboembolism in patients with liver cirrhosis: a nationwide cohort study in Taiwan , 2015, Journal of thrombosis and haemostasis : JTH.

[44]  D. Zillikens,et al.  Pemphigoid diseases , 2013, The Lancet.

[45]  Jaw-Town Lin,et al.  Long‐term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: A 10‐year nationwide cohort study , 2012, Hepatology.

[46]  E. Horváth-Puhó,et al.  Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population‐based case‐control study , 2012, Journal of thrombosis and haemostasis : JTH.

[47]  J. Sundquist,et al.  Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden , 2012, The Lancet.

[48]  D. Fanoni,et al.  Activation of coagulation in bullous pemphigoid and other eosinophil‐related inflammatory skin diseases , 2011, Clinical and experimental immunology.

[49]  Sreeram V Ramagopalan,et al.  Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study , 2011, BMC medicine.

[50]  S. Goldhaber Risk factors for venous thromboembolism. , 2010, Journal of the American College of Cardiology.

[51]  P. Meroni,et al.  Skin autoimmunity and blood coagulation , 2010, Autoimmunity.

[52]  R. Hubbard,et al.  A population‐based study of acute medical conditions associated with bullous pemphigoid , 2009, The British journal of dermatology.

[53]  Peter Cummings,et al.  The relative merits of risk ratios and odds ratios. , 2009, Archives of pediatrics & adolescent medicine.

[54]  D. Fanoni,et al.  Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications , 2009, The British journal of dermatology.

[55]  Cecilia Becattini,et al.  Cardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis , 2008, Circulation.

[56]  M. Inaoki,et al.  Antiphospholipid antibodies in patients with autoimmune blistering disease. , 2007, Journal of the American Academy of Dermatology.

[57]  M. Inaoki,et al.  Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases , 2006, Archives of Dermatological Research.

[58]  H. Sharif,et al.  Pulmonary embolism in pemphigus vulgaris, the need for judicious immunotherapy. , 2005, JPMA. The Journal of the Pakistan Medical Association.

[59]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[60]  M. Symons,et al.  Hazard rate ratio and prospective epidemiological studies. , 2002, Journal of clinical epidemiology.

[61]  L. Wang,et al.  High levels of interleukin‐8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T‐cell activities , 2000, The British journal of dermatology.

[62]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[63]  A. Mastroianni,et al.  The serum levels of sE‐selectin are increased in patients with bullous pemphigoid or pemphigus vulgaris. Correlation with the number of skin lesions and recovery after corsticosteroid therapy , 1997, The British journal of dermatology.

[64]  A. Ogdie,et al.  Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study , 2018, European heart journal.

[65]  F. Rosendaal,et al.  Venous thrombosis , 2015, Nature Reviews Disease Primers.

[66]  L. Sagi,et al.  Novel antiphospholipid antibodies in autoimmune bullous diseases. , 2014, Human antibodies.

[67]  Yu-Huei Huang,et al.  Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study. , 2012, The Journal of investigative dermatology.

[68]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.